Temozolomide

Temozolomide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Glioblastoma、Relapsed/Refractory Primary Central Nervous System Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Temozolomide 研究

• A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma

  I 期 / II 期招募中中国NCT07599371

• Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

  III 期招募中中国NCT06008106

• Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

  III 期招募中奥地利丹麦挪威瑞典NCT06419946

• Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors

  不适用招募中IranNCT07675070

• Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

  II 期招募中美国NCT04919382

• Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

  不适用招募中美国NCT04199026

• A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

  II 期招募中意大利NCT04893785

• IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

  III 期招募中美国澳大利亚BrazilCzechiaNCT07104032

• FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  I 期 / II 期招募中澳大利亚奥地利比利时CzechiaNCT04625907

• Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

  I 期 / II 期招募中美国NCT07346157

• Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

  II 期招募中中国NCT06514313

• The Efficacy and Safety of Temozolomide in SDH-deficient GIST

  II 期招募中South KoreaNCT05661643

• Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

  II 期招募中美国NCT07708961

• Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma

  II 期招募中中国NCT04961515

• Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

  II 期招募中美国NCT07225621

• Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression

  II 期招募中中国NCT07670026

• Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

  I 期招募中美国NCT07027748

• Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

  I 期招募中美国NCT06410248

• Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

  III 期招募中美国NCT07452458

• Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

  I 期招募中美国NCT05083754

• Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

  III 期招募中RussiaNCT07375563

• A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

  II 期 / III 期招募中美国加拿大丹麦法国NCT07549321

• A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

  II 期 / III 期招募中美国NCT06624644

• Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

  早期 I 期招募中美国NCT07025226

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。